Welcome to Cardiology Today – Recorded January 05, 2026. This episode summarizes 5 key cardiology studies on topics like left ventricular diastolic dysfunction and transcatheter aortic valve replacement. Key takeaway: RBMS1 Deficiency Improves Heart Failure.

Article Links:

Article 1: Major arrhythmias in non-dilated left ventricular cardiomyopathy: a novel prediction score. (European heart journal)

Article 2: Deficiency of the RNA-binding protein RBMS1 improves myocardial fibrosis and heart failure. (European heart journal)

Article 3: Coronary access after TAVR with the 4th and 5th -generation self-expanding Evolut valves: The EPROMPT-CA study. (International journal of cardiology)

Article 4: Durability of sotatercept response in pulmonary hypertension: Insights from extended real-world follow-up. (International journal of cardiology)

Article 5: Impact of Left Ventricular Diastolic Function on Right Ventricular Size and Function. (Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography)

Full episode page: https://podcast.explainheart.com/podcast/rbms1-deficiency-improves-heart-failure-01-05-26/

Journal: European heart journal

PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40678978

Summary: Researchers identified a cohort of 337 patients with non-dilated left ventricular cardiomyopathy, or NDLVC, without prior major arrhythmic events. The study developed a novel prediction score for the occurrence of the first major arrhythmic event in this patient population. Diagnostic workup including cardiac magnetic resonance, endomyocardial biopsy, and genetic testing contributed to the elements comprising this score. This prediction score facilitates improved risk stratification for serious arrhythmias in non-dilated left ventricular cardiomyopathy.

Journal: European heart journal

PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40471706

Summary: This study found that a deficiency of RNA-binding motif single-stranded interacting protein 1, or RBMS1, significantly improved both myocardial fibrosis and heart failure. Researchers observed that RBMS1 levels were elevated in the hearts of heart failure patients and animal models. The deficiency of RBMS1 regulated alternative splicing, which subsequently reduced cardiac fibrosis. These findings demonstrate RBMS1 as a novel therapeutic target for heart failure and myocardial fibrosis.

Journal: International journal of cardiology

PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41485619

Summary: This prospective study assessed coronary access immediately following transcatheter aortic valve replacement, or TAVR, using fourth and fifth-generation self-expanding Evolut F. X. and F. X. Plus valves. Researchers identified specific computed tomography predictors for selective coronary access in patients who underwent transfemoral TAVR. The study established the anatomical determinants that impact the feasibility of subsequent coronary interventions. These findings offer practical guidance for optimizing post-TAVR coronary access strategies in patients implanted with these latest Evolut valve platforms.

Journal: International journal of cardiology

PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41485617

Summary: This retrospective cohort study compared 454 patients with primary pulmonary hypertension receiving sotatercept to 963386 primary pulmonary hypertension patients who did not receive the treatment. Researchers utilized data from a global federated health research network to analyze real-world long-term outcomes. The study established a comprehensive comparison of patient trajectories between the sotatercept-treated and untreated cohorts over an extended follow-up period. These findings offer critical data on the sustained real-world impact of sotatercept in pulmonary hypertension beyond short-term trial observations.

Journal: Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography

PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41485609

Summary: This study investigated the impact of various degrees of left ventricular diastolic dysfunction, or D. D., on right ventricular size and function. Researchers performed 3-dimensional imaging of the right ventricle in a broad sample of 370 patients undergoing echocardiography. The study established a direct relationship between lesser degrees of left ventricular diastolic dysfunction and changes in right ventricular morphology and performance. These findings highlight that even mild or moderate left ventricular diastolic dysfunction can significantly influence right ventricular dimensions and functional capacity, extending beyond observations in severe heart failure with preserved ejection fraction, or H. F. pEF.

Today’s date is January 05, 2026. Welcome to Cardiology Today. Here are the latest research findings.

Article number one. Major arrhythmias in non-dilated left ventricular cardiomyopathy: a novel prediction score. Researchers identified a cohort of 337 patients with non-dilated left ventricular cardiomyopathy, or NDLVC, without prior major arrhythmic events. The study developed a novel prediction score for the occurrence of the first major arrhythmic event in this patient population. Diagnostic workup including cardiac magnetic resonance, endomyocardial biopsy, and genetic testing contributed to the elements comprising this score. This prediction score facilitates improved risk stratification for serious arrhythmias in non-dilated left ventricular cardiomyopathy.

Article number two. Deficiency of the RNA-binding protein RBMS1 improves myocardial fibrosis and heart failure. This study found that a deficiency of RNA-binding motif single-stranded interacting protein 1, or RBMS1, significantly improved both myocardial fibrosis and heart failure. Researchers observed that RBMS1 levels were elevated in the hearts of heart failure patients and animal models. The deficiency of RBMS1 regulated alternative splicing, which subsequently reduced cardiac fibrosis. These findings demonstrate RBMS1 as a novel therapeutic target for heart failure and myocardial fibrosis.

Article number three. Coronary access after TAVR with the 4th and 5th -generation self-expanding Evolut valves: The EPROMPT-CA study. This prospective study assessed coronary access immediately following transcatheter aortic valve replacement, or TAVR, using fourth and fifth-generation self-expanding Evolut F. X. and F. X. Plus valves. Researchers identified specific computed tomography predictors for selective coronary access in patients who underwent transfemoral TAVR. The study established the anatomical determinants that impact the feasibility of subsequent coronary interventions. These findings offer practical guidance for optimizing post-TAVR coronary access strategies in patients implanted with these latest Evolut valve platforms.

Article number four. Durability of sotatercept response in pulmonary hypertension: Insights from extended real-world follow-up. This retrospective cohort study compared 454 patients with primary pulmonary hypertension receiving sotatercept to 963386 primary pulmonary hypertension patients who did not receive the treatment. Researchers utilized data from a global federated health research network to analyze real-world long-term outcomes. The study established a comprehensive comparison of patient trajectories between the sotatercept-treated and untreated cohorts over an extended follow-up period. These findings offer critical data on the sustained real-world impact of sotatercept in pulmonary hypertension beyond short-term trial observations.

Article number five. Impact of Left Ventricular Diastolic Function on Right Ventricular Size and Function. This study investigated the impact of various degrees of left ventricular diastolic dysfunction, or D. D., on right ventricular size and function. Researchers performed 3-dimensional imaging of the right ventricle in a broad sample of 370 patients undergoing echocardiography. The study established a direct relationship between lesser degrees of left ventricular diastolic dysfunction and changes in right ventricular morphology and performance. These findings highlight that even mild or moderate left ventricular diastolic dysfunction can significantly influence right ventricular dimensions and functional capacity, extending beyond observations in severe heart failure with preserved ejection fraction, or H. F. pEF.

Thank you for listening. Don’t forget to subscribe.

left ventricular diastolic dysfunction, transcatheter aortic valve replacement, heart failure, alternative splicing, TAVR, therapeutic target, Evolut valve, prediction score, RNA-binding protein RBMS1, cardiac magnetic resonance, sotatercept, long-term outcomes, major arrhythmic event, myocardial fibrosis, real-world data, 3-dimensional echocardiography, H. F. pEF, TriNetX network, NDLVC, right ventricular function, pulmonary hypertension, coronary access, heart failure with preserved ejection fraction, computed tomography, non-dilated left ventricular cardiomyopathy.

Concise summaries of cardiovascular research for professionals.

Subscribe • Share • Follow

The post RBMS1 Deficiency Improves Heart Failure 01/05/26 first appeared on Cardiology Today.